- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.06. | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.05. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Alpha Teknova Q1 2025 slides: improved margins despite mixed revenue performance | 2 | Investing.com | ||
| 08.05. | Alpha Teknova GAAP EPS of -$0.09, revenue of $9.8M | 2 | Seeking Alpha | ||
| ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
| 25.04. | Alpha Teknova, Inc.: Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 | 1 | GlobeNewswire (USA) | ||
| 19.03. | Alpha Teknova, Inc.: Teknova and Pluristyx Launch Proprietary PluriFreeze Cryopreservation System to Accelerate the Development of Cell Therapies | 1 | GlobeNewswire (USA) | ||
| 12.03. | Teknova and Pluristyx join hands to streamline next-generation cell therapy production | 3 | Seeking Alpha | ||
| 12.03. | Alpha Teknova, Inc.: Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies | 1 | GlobeNewswire (USA) | ||
| 07.03. | Alpha Teknova, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 05.03. | Alpha Teknova stock holds as KeyBanc maintains rating | 1 | Investing.com | ||
| 04.03. | Alpha Teknova, Inc. Q4 Loss Narrows | 1 | RTTNews | ||
| 04.03. | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2024 Financial Results | 418 | GlobeNewswire (Europe) | Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides... ► Artikel lesen | |
| 04.03. | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.02. | Alpha Teknova, Inc.: Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 | 1 | GlobeNewswire (USA) | ||
| 12.02. | Here's What Boosted Alpha Teknova (TKNO) in Q4 | 1 | Insider Monkey | ||
| 10.02. | Craig-Hallum initiates Alpha Teknova stock with buy rating | 1 | Investing.com | ||
| 09.07.24 | Alpha Teknova, Inc.: Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results | 472 | GlobeNewswire (Europe) | Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 26,680 | 0,00 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 20,640 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,010 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| RELAY THERAPEUTICS | 3,600 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support... ► Artikel lesen | |
| EVOTEC | 7,458 | +1,47 % | Evotec, Lanxess, Northern Data, Redcare Pharmacy, Renk Group, Vonovia - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 44,370 | 0,00 % | Guggenheim reiterates Buy on Apogee Therapeutics stock ahead of key data | ||
| QIAGEN | 41,170 | +1,06 % | Kurs von Qiagen NV steigt etwas (41,29 €) | Am Aktienmarkt notiert der Anteilsschein von Qiagen NV derzeit ein wenig fester. Zuletzt zahlten Investoren für das Wertpapier 41,29 Euro. Heute hat sich im Wertpapierhandel die Qiagen NV-Aktie zwischenzeitlich... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 44,530 | 0,00 % | Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion | ||
| ARRIVENT BIOPHARMA | 21,100 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 11,215 | 0,00 % | BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside | ||
| ARCELLX | 66,28 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ALUMIS | 3,280 | 0,00 % | Alumis Inc.: Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis | SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 27,460 | 0,00 % | Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth | ||
| JADE BIOSCIENCES | 10,800 | 0,00 % | Jade Biosciences Appoints Brad Dahms as Chief Financial Officer | SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies... ► Artikel lesen | |
| DISC MEDICINE | 53,17 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen |
Das Unternehmen ALPHA TEKNOVA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TEKNOVA INC finden Sie auf Wallstreet Online.